⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT April 21, 2026

Rifoldin 600 mg Trockensubstanz zur Infusionsbereitung mit Lösungsmittel 600 mg (Pulver und Lösungsmittel zur Herstellung einer Infusionslösung)

📷 Wikipedia: Rifampicin · Source
Rifoldin 600 mg Trockensubstanz zur Infusionsbereitung mit Lösungsmittel 600 mg (Pulver und Lösungsmittel zur Herstellung einer Infusionslösung)
📷 Wikipedia: Rifampicin · Source
Parallel export ban in effect.
✅
Resolved by agency
The issuing agency has confirmed this medicine alert is over — the underlying issue was addressed. Originally reported 36 days ago.
📈 Timeline
2 days in total
May 18, 2026 May 20, 2026

What is this? This is a powder and liquid used to make an antibiotic drip. It contains rifampicin and is made by Sanofi-Aventis.

What's happening? The medicine is not available right now. It will come back in late May.

Does this affect me? If you need this drip in Austria, you may not be able to get it until then.

What should I do? Ask your pharmacist or doctor for advice if you are waiting for this treatment.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
RIFAMPICIN
Agency-published detail

🚫 Parallel export ban active · ATC: J04AB02 · Reason: Verzögerung bei der Herstellung · Marketing authorisation holder: Sanofi-Aventis GmbH, Turm A, 29. OG, Wienerbergstraße 11, 1100 Wien, Österreich · Affected packs: 1 Stück Schachtel, Ampulle, Durchstechflasche [Nicht verfügbar, since 2026-04-17, resupply 2026-05-25]

First published
April 21, 2026
Last refreshed by us
1 week ago
Severity (as classified)
Low
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

Medium AT 5 months ago

Eremfat 600 mg - Filmtabletten (Filmtablette)

Parallel export is banned for this medicine.
Medium AT 5 months ago

Eremfat 450 mg - Filmtabletten (Filmtablette)

Eremfat 450 mg film-coated tablets are subject to a parallel export ban.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Rifoldin 600 mg Trockensubstanz zur Infusionsbereitung mit Lösungsmittel 600 mg (Pulver und Lösungsmittel zur Herstellung einer Infusionslösung). Parallel export ban in effect.
▸ When was this alert issued?
This alert was issued on April 21, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Low risk. A low risk means harm is unlikely under normal use. The alert is informational but still worth reading.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.